Collegium Pharmaceutical (COLL) Enterprise Value (2014 - 2026)

Collegium Pharmaceutical's Enterprise Value history runs 13 years deep, the most recent figure standing at -$288.5 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 45.87% year-over-year to -$288.5 million; the TTM figure through Mar 2026 stood at -$288.5 million (down 45.87% YoY), while the FY2025 annual figure was -$251.1 million, down 162.76% from the prior year.
• Enterprise Value was -$288.5 million for Q1 2026 at Collegium Pharmaceutical, down from -$251.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$95.6 million in Q4 2024 to a low of -$325.5 million in Q2 2023.
• Historically, Enterprise Value has averaged -$223.4 million across 5 years, with a median of -$251.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value sank 165.21% in 2023, then jumped 69.23% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$173.7 million in 2022, then sank by 78.8% to -$310.5 million in 2023, then surged by 69.23% to -$95.6 million in 2024, then plunged by 162.76% to -$251.1 million in 2025, then retreated by 14.89% to -$288.5 million in 2026.
• The last three Enterprise Value figures came in at -$288.5 million (Q1 2026), -$251.1 million (Q4 2025), and -$285.9 million (Q3 2025), per Business Quant data.